Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Grahame Mark Jeffery"'
Autor:
Michael B. Jameson, Kirsten Gormly, David Espinoza, Wendy Hague, Gholamreza Asghari, Grahame Mark Jeffery, Timothy Jay Price, Christos Stelios Karapetis, Michael Arendse, James Armstrong, John Childs, Frank A. Frizelle, Sam Ngan, Andrew Stevenson, Martinus Oostendorp, Stephen P. Ackland
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late
Externí odkaz:
https://doaj.org/article/631cd481e261422aa5a9a4ae454d866e
Autor:
Michael B. Jameson, Kirsten Gormly, David Espinoza, Wendy Hague, Grahame Mark Jeffery, Timothy Jay Price, Christos Stelios Karapetis, Michael Arendse, James Armstrong, John Childs, Frank Frizelle, Samuel Y Ngan, Andrew Stevenson, Rix Du Plessis, Swetha Sridharan, Matthew E. Burge, Stephen P. Ackland
Publikováno v:
Journal of Clinical Oncology. 40:TPS3646-TPS3646
TPS3646 Background: In retrospective studies statin use during preoperative chemo-radiation (pCRT) for rectal cancer is associated with improved overall survival, pathological tumor response and treatment toxicity. In vivo preclinical studies show th
Autor:
Martinus Oostendorp, Timothy J. Price, Michael B. Jameson, James Armstrong, Andrew R. L. Stevenson, Christos S. Karapetis, David Espinoza, Wendy Hague, Gholamreza Asghari, Kirsten Gormly, Michael Arendse, Samuel Y Ngan, Stephen P. Ackland, Frank A. Frizelle, Grahame Mark Jeffery, John Childs
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Cancer
BMC Cancer
Background Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late toxicitie
Autor:
J.N. Scott, Katrina Sharples, G. Riley, Stephanie Pollard, M.V. Dzhelali, Blair McLaren, Grahame Mark Jeffery, Andrew Simpson, Vernon Harvey, Victoria Hinder, Michael Findlay, Michael B. Jameson, Richard Isaacs
Publikováno v:
Annals of Oncology. 24:1828-1834
Background: Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have nonoverlapping toxic effects and synergy pre-clinically. We explored the efficacy and toxic effect of an all-oral combination of capecitabine with
Autor:
Xavier Sagaert, Igor Kiss, Grahame Mark Jeffery, Evaristo Maiello, Zacharenia Saridaki, Valentina Pomella, Sandra Merino, Pratyaksha Wirapati, Peter Kerr, Meinolf Karthaus, Anca C. Mihailov, Joseph McKendrick, Razvan-Ovidiu D. Curca, Sabine Tejpar, Ben Vandenbosch, John Bridgewater
Publikováno v:
Journal of Clinical Oncology. 35:3538-3538
3538 Background: Addition of (ziv)-aflibercept (A) to FOLFIRI in second-line therapy for metastatic colorectal cancer (CRC) has been shown to be beneficial in phase III VELOUR trial (NCT00561470). A follow-up study (NCT01754272) was undertaken to acq
Autor:
Michael B. Jameson, Manuel Hidalgo, F. Parnis, P. Grimson, Prasad Cooray, R. Stagg, Alfredo Carrato, Niall C. Tebbutt, Jakob Dupont, Grahame Mark Jeffery
Publikováno v:
Annals of Oncology. 25:iv210
Aim: Delta-like ligand 4 (DLL4) is a ligand that activates the Notch pathway. DEM is a humanized IgG2 anti-DLL4 antibody that inhibits tumor growth & decreases cancer stem cell frequency in minimally passaged human xenograft models. In addition, DEM